Repare Therapeutics Inc

Repare Therapeutics — Technical Presentation (December 2024)

47 slides from Repare Therapeutics's technical presentation, Dec 12, 2024

  1. Slide 1: MYTHIC Lunre+Camo Clinical Data Update

    MYTHIC Lunre+Camo Clinical Data Update December 12, 2024

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “expects,” “intends,” “pla

  3. Slide 3: Today's agenda

    Today’s agenda Introduction: About Repare 1 Lloyd M. Segal President & CEO Repare Therapeutics Today’s Focus: Gynecologic Cancers 2 Brian Slomovitz, MD Director of Gynecologic Oncology Mount Sinai Medical Center MYTHIC Lunresertib + Camonsertib Data 3 Maria Koehler, MD, PhD Paul Basciano, MD EVP and

  4. Slide 4: Introduction: About Repare

    Introduction: Lloyd M. Segal President & CEO About Repare Repare Therapeutics

  5. Slide 5: Advancing pipeline of precision oncology therapeutics

    Advancing pipeline of precision oncology therapeutics Repare’s mission is to apply synthetic lethal biology to bring practice-changing, precision therapies to patients who need them Program Tumor lesion Drug target Preclinical Ph 1 Ph 2 Ph 3 Rights Camonsertib Combination Today’s Focus Lunresertib C

  6. Slide 6: POC achieved for registrational trial; Ph 3 EC start in 2025

    POC achieved for registrational trial; Ph 3 EC start in 2025 We achieved POC for lunre+camo combo in EC and PROC ï,§ Combination was effective and well-tolerated ï,§ Clear signals, opportunity for registrational trials in both EC and PROCï,§ Opportunity to deliver important, new and chemo-alternativ

  7. Slide 7: Some key terms and abbreviations in today's discussion

    Some key terms and abbreviations in today’s discussion Term Abbreviation AE Adverse events Camo Camonsertib, a proprietary ATR inhibitor EC Endometrial cancer ICI Immune checkpoint inhibitor (e.g., PD-1 and PD-L1) Lunre Lunresertib, a proprietary PKMYT1 inhibitor Lunre BM+ lunre-sensitizing biomarke

  8. Slide 8: Our mechanistic rationale for lunre+camo

    Our mechanistic rationale for lunre+camo Lunresertib (PKMYT1i) + camonsertib (ATRi) enhance CDK1 activation and premature mitosis References: 1 ANE poster B057: Gallo et al. Preclinical development of PKMYT1 and ATR inhibitor combinations. ATR, ataxia telangiectasia and Rad-3 related; CDC25, cell di

  9. Slide 9: MYTHIC clinical trial: Lunre+camo background and overview

    MYTHIC clinical trial: Lunre+camo background and overview 2021 H1 2023 H2 2023 2024 Initiated MYTHIC, first First topline data: Established initial RP2D EC and PROC data at optimized clinical trial targeting monotherapy and lunre + RP2D (n=51) as of Nov 14, 2024 PKMYT1 inhibition camo combination (s

  10. Slide 10: Lunre+camo today in EC and PROC

    Lunre+camo today in EC and PROC A potentially effective, well-tolerated, convenient and differentiated option Overall ï,§ Encouraging efficacy in heavily pre-treated patients with adverse genomic profile and worse prognosesï,§ Promising rate of tumor responses, durable benefitï,§ Potential alternati

  11. Slide 11: Today's Focus: Gynecologic Cancers

    Today’s Focus: Gynecologic Cancers Brian Slomovitz, MD, MS, FACOG Director, Gynecologic Oncology Co-Chair of Cancer Research Committee Mount Sinai Medical Center, Miami Beach Professor, Obstetrics and Gynecology Florida International University Member, Board of Directors GOG Foundation Uterine Cance

  12. Slide 12: Endometrial cancer in 2024

    Endometrial cancer in 2024 ï,§ Only gynecologic cancer with rising incidence and mortality ï,§ Has now exceeded ovarian cancer in annual estimated deaths ï,§ Corrected for hysterectomy rates, uterine cancer is the 2nd most common cancer among women 67,880 new cases 13,250 deaths ~2/3 will be early s

  13. Slide 13: Endometrial SOC has evolved to be molecularly focused

    Endometrial SOC has evolved to be molecularly focused Progestin Combination chemotherapy TCGA FIGO staging updated Hormonal treatment of EC established as SoC (GOG177 Ph 3) Molecular subgroups Molecular classifications Chemotherapy for advanced or incorporated recurrent EC 1961 1988 2004 2009 2013 2

  14. Slide 14: IO+Chemo: New 1st line SOC, but benefit mostly in dMMR population

    IO+Chemo: New 1st line SOC, but benefit mostly in dMMR population Impressive benefit in dMMR (<30%) dMMR tumors Less benefit in pMMR (>70+%) pMMR tumors MYTHIC tumors are pMMR Approval for “all comers” 14 Abbreviations: dMMR, deficient mismatch repair; pMMR, proficient mismatch repair. Note: Slide c

  15. Slide 15: After chemotherapy + immune checkpoint inhibitor (ICI)

    After chemotherapy + immune checkpoint inhibitor (ICI)… The NCCN guided treatment is single agent chemotherapy… What do I, as a gynecologic oncologist, need for my patients with endometrial cancer? 1. Treatment solution after patients received ICI and chemotherapy – especially pMMR • Lunre+camo data

  16. Slide 16: Tumors with Lunre BM+ have significantly worse outcomes

    Tumors with Lunre BM+ have significantly worse outcomes Probability of survival for a subset of 30% of patients with Lunre BM+ (CCNE1, PPP2R1A, FBXW7) Endometrial Cancer1 Ovarian Cancer1 Biomarker 1.00 Lunre BM- 1.00 Biomarker Lunre BM+ Lunre BM-Lunre BM+ 0.75 0.75 P=0.003 probability 0.50 0.50 prob

  17. Slide 17: Ovarian Cancer: Natural history

    Ovarian Cancer: Natural history – we have chemotherapy… Diagnosis Evaluation Progression Death Symptoms Chemo 1 Maintenance Chemo #2 Chemo #3 Chemo #4+ Platinum based Platinum? Supportive Care Staging/Debulking Progression-Free Survival Post Progression Survival (12-28 mos) (12-38 mos) • 19,680 wome

  18. Slide 18: Opportunity to meet urgent patients' needs with a chemo-free regimen

    Opportunity to meet urgent patients’ needs with a chemo-free regimen Lunre BM status is linked to significantly reduced mOS Attractive chemotherapy-free regimen with comparable efficacy to emerging ADC is needed We need studies applying tumor selection – the right approach that helps patients the mo

  19. Slide 19: MYTHIC Study Data

    MYTHIC Study Data Maria Koehler, M.D., Ph.D. EVP, Chief Medical Officer Repare Therapeutics Paul Basciano, M.D. VP, Clinical Development & Medical Affairs Repare Therapeutics

  20. Slide 20: Overview of clinical data presentation

    Overview of clinical data presentation Overall results observed in gynecologic tumors Endometrial cancer data Platinum-resistant ovarian cancer data Key perspectives on our MOA-driven response profile and our differentiation Registrational path forward for endometrial cancer 20

  21. Slide 21: Significant overall efficacy observed with lunre+camo in gyn tumors

    Overall results observed in gynecologic tumors Significant overall efficacy observed with lunre+camo in gyn tumors Tumor shrinkage with lunre+camo in recurrent gynecologic cancers Note: +, denotes treatment ongoing In efficacy-evaluable patients with EC or PROC at RP2D: ï,§ 73% of patients had tumor

  22. Slide 22: Similar efficacy seen across all BM+ subsets in PROC and EC

    Overall results observed in gynecologic tumors Similar efficacy seen across all BM+ subsets in PROC and EC Duration on therapy by genomic lesion Note: +, denotes treatment ongoing Best degree of tumor shrinkage on therapy 22

  23. Slide 23: Favorable safety and tolerability vs. current and emerging treatments

    Overall results observed in gynecologic tumors Favorable safety and tolerability vs. current and emerging treatments Safety profile and tolerability at RP2D RP2D (all tumors; optimized dose) (N=67) All Grade Grade 3 Grade 4 TRAEs in ≥10% of patients n (%) n (%) n (%) Any Event 61 (91.0) 29 (43.3) 2

  24. Slide 24: Lunre+camo potentially addresses unmet need in 2L+ EC

    Endometrial cancer results Lunre+camo potentially addresses unmet need in 2L+ EC Patients heavily pre-treated, tumors with poor prognoses at study entry Endometrial cancer N=27 Heavily pre-treated patients:ï,§ 100% prior platinum therapyï,§ 77.8% received prior ICIsï,§ 59% treated as 4th line or bey

  25. Slide 25: EC: Meaningful clinical benefit across histological subtypes

    Endometrial cancer results EC: Meaningful clinical benefit of across histological subtypes Duration of treatment on lunre+camo Genotype FBXW7 PPP2R1A CCNE1 PPP2R1A PPP2R1A FBXW7 PPP2R1A PPP2R1A CCNE1/PPP2R1A CCNE1/PPP2R1A FBXW7 FBXW7 FBXW7 FBXW7 PPP2R1A CCNE1 PPP2R1A CCNE1 PPP2R1A PPP2R1A PPP2R1A PP

  26. Slide 26: EC: Deep and durable responses across all lunre BM+ subsets

    Endometrial cancer results EC: Deep and durable responses across all lunre BM+ subsets 70% of patients experienced tumor shrinkage ORR (conf.+ unconf.), % 25.9% ORR (conf.), % 18.5% CR 1 (3.7%) PR 4 (14.8%) Durable responses observed across histologies and biomarkers 16 weeks 80 Dose / Schedule: RP2

  27. Slide 27: PROC: Lunre+camo addresses poor prognosis and chemo-resistance

    PROC results PROC: Lunre+camo addresses poor prognosis and chemo-resistance Patients heavily pre-treated, tumors with poor prognostic features PROC Patients N=24 Heavily pre-treated patients:ï,§ 100% platinum-resistant or platinum ineligibleï,§ 45.8% received prior PARPiï,§ 70.8% received prior beva

  28. Slide 28: PROC: Compelling clinical benefit rate of 79% observed

    PROC results PROC: Compelling clinical benefit rate of 79% observed Duration of treatment on lunre+camo Genotype CCNE1 FBXW7 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 PPP2R1A CCNE1/FBXW7 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CCNE1 CR/PR, confirmed CCNE1 CR/PR, unconfirmed CCNE1 CCNE1

  29. Slide 29: PROC: Strong efficacy in lunre BM+ tumors

    PROC results PROC: Strong efficacy in lunre BM+ tumors 75% of patients experienced tumor shrinkage ORR (conf.+ unconf.), % 37.5% ORR (conf.), % 16.7% PR 4 (16.7%) Durable responses observed across subtypes and genetic alterations 16 weeks 80 Dose / Schedule: RP2d (80BID) Lesions 60 Target 40 in 20 2

  30. Slide 30: MOA-driven response profile and differentiation

    MOA-driven response profile and differentiation EC & PROC: Pattern of benefit consistent with lunre MOA Lunre+camo combination demonstrated: ï,§ Strong and consistent evidence of anti-tumor activity observed in both tumors despite poor prognosis of BM+ populationï,§ Durable clinical benefit, includi

  31. Slide 31: Greater clinical benefit observed vs. prior treatments

    MOA-driven response profile and differentiation Greater clinical benefit observed vs. prior treatments Duration of treatment (DOT) on lunre+camo vs. previous therapy Patients with >5mo DOT Last Line DOT Lunre+Camo DOT OC EC EC OC OC OC EC EC OC EC EC OC EC OC // EC // OC Months Months ï,§ Patients a

  32. Slide 32: Durable clinical benefit in patients with unconfirmed PRs

    MOA-driven response profile and differentiation Durable clinical benefit in patients with unconfirmed PRs Tumor lesion change observed for tumors with unconfirmed PRs EC and PROC pts with final best overall response of uPR EC PROC ï,§ Continuous tumor burden reduction culminating in benefit in patie

  33. Slide 33: Lunre+camo safety profile: Differentiation from emerging ADCs

    MOA-driven response profile and differentiation Lunre+camo safety profile: Differentiation from emerging ADCs Safety Lunre+camo ADCs Dosingï,§ Oralï,§ IV High-grade toxicitiesï,§ Overall Gr3/4* TRAEs: 46.3%ï,§ Generally higher Gr3/4 TRAEs: ~30-70+%ï,§ No treatment-related deathsï,§ Treatment-related

  34. Slide 34: Lunre+camo: Clinical summary and development path forward

    Registrational path forward for endometrial cancer Lunre+camo: Clinical summary and development path forward A potentially effective, well-tolerated, convenient and differentiated option Overall ï,§ Encouraging efficacy in heavily pre-treated patients with adverse genomic profile and worse prognoses

  35. Slide 35: Pivotal development for EC supported by data and regulators

    Registrational path forward for endometrial cancer Pivotal development for EC supported by data and regulators Path forward Focus on EC Pivotal trial start in 2025ï,§ 2L+ target and robust patient need for chemo alternatives ï,§ Large, growing and global unmet needï,§ EU and FDA regulatory alignment

  36. Slide 36: Efficient plan to regulatory approval: EC as lead indication

    Registrational path forward for endometrial cancer Efficient plan to regulatory approval: EC as lead indication Phase II Study with Alliance Foundation Trials Lunre monotherapy A andSmall IRB comple study e to establish contribution of components d for Dec24 N = 20 ENDOMAP Random-ï,§ Ph 2 study with

  37. Slide 37: Ph 3 registrational trial in EC

    Registrational path forward for endometrial cancer Ph 3 registrational trial in EC Supporting NDA submission for potential accelerated and full approvals within one study Eligibility criteria: ï,§ Recurrent EC or carcinosarcoma ï,§ Previous ICI and platinum ï,§ At least 1 evaluable lesion ï,§ 1-3 pr

  38. Slide 38: EC as lead indication: Targeting 2028 NDA submission

    Registrational path forward for endometrial cancer EC as lead indication: Targeting 2028 NDA submission Anticipated milestones starting with Q1 2025 initiation of COC trial Q1 2025 H2 2025 2026 2027 2028 COC Trial Ph 3 Trial Start COC Trial FDA Accelerated FDA Full Approval Start Readout Approval Re

  39. Slide 39: Patient and Commercial Opportunity

    Patient and Commercial Opportunity Phillip Herman EVP, Chief Commercial and Portfolio Development Officer Repare Therapeutics

  40. Slide 40: Commercial overview: Building a strong foundation

    Commercial overview: Building a strong foundation Strong commercial opportunity ï,§ De-risked opportunity in EC and PROC ï,§ EC is our lead indication, with potential for Accelerated Approval built into designï,§ PROC, a future life-cycle opportunity ï,§ Clear value proposition for lunre+camo relati

  41. Slide 41: Lunre+camo combination well-positioned for success in 2L+ EC

    Lunre+camo combination well-positioned for success in 2L+ EC ï,§ New 1L standard of care will lead to majority of 2L patients having previously received ICI + chemoï,§ Limited data to support use of approved 2L options after ICI + chemo, opportunity for novel agents Phase II Study with Alliance Foun

  42. Slide 42: EC offers meaningful commercial potential as lead indication

    EC offers meaningful commercial potential as lead indication ~2.9K Addressable 2L EC US Patients1 ~$450M – $600M U.S. Market Potential2 ~$900M – $1.2B Global Market Potential3 Target Label Lunre+camo indicated for adult patients with CCNE1, FBXw7, PPP2R1a altered, serous, endometroid or carcinosarco

  43. Slide 43: Lunre combinations offer significant market opportunity potential

    Lunre combinations offer significant market opportunity potential Potential for multiple additional tumor types beyond EC Initial target indication: ~$900M—$1.2B market potential Endometrial Cancer Additional de-risked opportunity: >$2B market size in 2030* Ovarian Cancer Multiple indication expansi

  44. Slide 44: Closing Remarks

    R=PARE THERAPEUTICS Closing Remarks

  45. Slide 45: POC achieved for registrational trial, Ph 3 EC start in 2025

    POC achieved for registrational trial, Ph 3 EC start in 2025 We achieved POC for lunre+camo combo in EC and PROC Combination was effective and well-tolerated Clear signals, opportunity for registrational trials in both EC and PROC Opportunity to deliver important, new and chemo-alternative treatment

  46. Slide 46: Questions & Answers

    Questions & Answers Lloyd Segal President, Chief Executive Officer Repare Therapeutics Brian Slomovitz, MD, MS, FACOG Director, Gynecologic Oncology Co-chair of the Cancer Research Center Mount Sinai Medical Center Maria Koehler, M.D., Ph.D. EVP, Chief Medical Officer Repare Therapeutics Phillip Her

  47. Slide 47: Thank you.

    Thank you. RepareRx.com ©2024 Repare Therapeutics

Repare Therapeutics — Technical Presentation (December 2024) on 6ix